home / stock / mbio / mbio news

MBIO News and Press, Mustang Bio Inc. From 03/28/23

Stock Information
Company Name: Mustang Bio Inc.
Stock Symbol: MBIO
Market: NASDAQ
Website: mustangbio.com
Menu
MBIO MBIO Quote MBIO Short MBIO News MBIO Articles MBIO Message Board
Get MBIO Alerts

News, Short Squeeze, Breakout and More Instantly...
MBIO - Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

WORCESTER, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures fo...
MBIO - Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

WORCESTER, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for...

MBIO - Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

MB-106 clinical trial under Mustang’s IND continues to enroll patients Additional IND filing and published research expected in 2023 across portfolio WORCESTER, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-s...

MBIO - Mustang Bio GAAP EPS of -$0.18 beats by $0.02

Mustang Bio press release ( NASDAQ: MBIO ): Q3 GAAP EPS of -$0.18 beats by $0.02 . As of September 30, 2022, Mustang’s cash and cash equivalents and restricted cash totaled $92.4 million, compared to $108.4 million at June 30, 2022 and $110.6 million as of Decem...
MBIO - Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...

MBIO - Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage b...

MBIO - Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Enrollment continues in clinical trial of MB-106 under Mustang’s IND; next data disclosure anticipated 4Q 2022 Ongoing clinical trial of MB-106 at Fred Hutch continues to demonstrate high efficacy, durable responses, and favorable safety profile across wide range of hematol...
MBIO - Mustang Bio: This Horse May Gallop Still

Summary We are circling back on small CAR-T developmental firm Mustang Bio, Inc. today for the first time in nearly a year and a half. The stock has been under pressure since we last looked in on this story, and the shares currently trade for less than net cash on the company's ba...

MBIO - Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

WORCESTER, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, so...

MBIO - Mustang Bio (MBIO) Corporate Presentation - Slideshow

The following slide deck was published by Mustang Bio, Inc. in conjunction with this event. For further details see: Mustang Bio (MBIO) Corporate Presentation - Slideshow

Previous 10 Next 10